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Abstract  
Aim: To assess efficacy (event-free survival, EFS) and safety in patients 
followed up for 3 years in the PrefHer study (NCT01401166). 
Patients and methods: Post-surgery and -chemotherapy in the 
(neo)adjuvant setting, patients with HER2-positive early breast cancer were 
randomised to receive four cycles of the subcutaneous form of trastuzumab 
(Herceptin® SC [H SC] via single-use injection device [Cohort 1] or delivery via 
a hand-held syringe from an SC Vial [Cohort 2]; 600 mg fixed dose) followed 
by four of the intravenous form of trastuzumab (Herceptin® [H IV]; 8 mg/kg 
loading, 6 mg/kg maintenance doses) in the adjuvant setting, or vice versa, 
every 3 weeks. Patients could have received H before randomisation. H was 
then continued to complete a total of 18 cycles, including any cycles received 
before randomisation. 
Results: A total of 488 patients were randomised across both cohorts. After 
median follow-up of 36.1 months, 3-year EFS across both groups in the 
evaluable intention-to-treat population (467 patients) was 90.6% overall, 
89.9% in Cohort 1, and 91.1% in Cohort 2. No new safety signals were 
identified during long-term follow-up, with only one cardiac serious adverse 
event in the safety population (483 patients). 
Conclusions: Three-year EFS data following H SC and H IV treatment are 
consistent with those reported by previous trials for H in the adjuvant setting. 
The overall safety profile during adjuvant treatment was as expected. 
 
Word count: 226/250  
 
1. Introduction 
Trastuzumab (Herceptin® [H], F. Hoffmann-La Roche Ltd, Basel, Switzerland)-
containing regimens are now standard of care for patients with HER2-positive 
breast cancer. A 600 mg fixed-dose manual injection of the subcutaneous 
form of H (Herceptin® SC [H SC], F. Hoffmann-La Roche Ltd), given via hand-
held syringe from an H SC Vial, was approved following demonstrated non-
inferiority compared with the intravenous form of H (H IV) based on 
pathological complete response and serum trough concentration in the 
HannaH study.[1] To date, over two million patients with breast cancer have 
been treated with H; approximately 80,000 of which were treated with H SC 
(F. Hoffmann-La Roche Ltd, data on file). The international, open-label, 
randomised, crossover PrefHer study (NCT01401166) investigated patient 
preference for H SC or H IV during the adjuvant treatment of HER2-positive 
early breast cancer. The study revealed overwhelming patient preferences for 
H SC (89%), regardless of the method of H SC delivery: single-use injection 
device (SID) or delivery via a hand-held syringe from an SC Vial, with ‘time 
saving’ and ‘less pain/discomfort/side effects’ the most common reasons 
given by the patients themselves during interviews.[2–4] There was a high 
preference for H SC irrespective of whether or not patients received H IV prior 
to study enrolment.[2,3] In addition, patients’ preferences for H SC for 
metastatic breast cancer have been demonstrated in the Metaspher study.[5] 
A time-and-motion study within the PrefHer study demonstrated a mean time 
saving of 55–57 min of patient chair time and 13–17 min of active healthcare 
professional time per session with H SC compared with H IV,[6] and several 
countries have reported estimated increased hospital capacity and/or cost-
savings with H SC.[7–17] These data support a transition to SC delivery.  
We present efficacy and safety data after 3 years’ follow-up in the PrefHer 
study.  
 
2. Patients and Methods  
2.1 Patients 
Eligibility criteria have been described previously [2] and are available in the 
appendix.  
 
2.2 Study design 
Following surgery and completion of chemotherapy in the (neo)adjuvant 
setting, patients received four cycles of H SC (600 mg fixed dose injected over 
approximately 5 min into the thigh) every 3 weeks followed by four cycles of H 
IV (6 mg/kg) in the adjuvant setting, or vice versa (Fig. 1).[2] An H IV loading 
dose of 8 mg/kg was required only if the first cycle of study treatment was the 
initial IV dose of H (i.e., H IV/H SC); otherwise, the dose was 6 mg/kg every 3 
weeks. Following these eight cycles (the crossover period), patients continued 
H SC or H IV therapy to complete 18 standard cycles (1 year) (H continuation 
period).  
During crossover, patients in Cohort 1 received H SC via SID and patients in 
Cohort 2 received H SC via hand-held syringe from an H SC Vial.  
Patients could have been either H-naïve (de novo) or could have already 
started H for early breast cancer prior to study entry (non-de novo), but 
needed to receive at least eight more cycles to complete 1 year (18 cycles) of 
H in the adjuvant setting. 
Following crossover, i.e. the H continuation period, it was planned for patients 
in Cohort 1 to receive H IV (unless choosing to self-administer H SC via SID), 
and for patients in Cohort 2 to receive H SC via hand-held syringe from an H 
SC Vial. 
Following completion of H, patients were followed up for 3 years from 
randomisation (follow-up period).  
The primary endpoint was patient preference (reported previously).[2,3] 
Secondary endpoints included event-free survival, safety and tolerability. 
PrefHer was conducted in accordance with Good Clinical Practice guidelines 
and the Declaration of Helsinki. All participating patients provided written 
informed consent. Approval for the protocol was obtained from appropriate 
local and national independent ethics committees. 
 
2.3 Statistical considerations 
EFS was assessed using the Kaplan–Meier approach and is presented for the 
overall evaluable intention-to-treat (ITT) populations (patients who completed 
the primary preference question and ≥1 administration of both H SC and H IV) 
for each cohort, and overall. EFS was defined as the time from randomisation 
to local, regional or distant disease recurrence, contralateral breast cancer or 
death from any cause. 
Adverse events (AEs) and serious AEs (SAEs) were reported according to 
National Cancer Institute – Common Terminology Criteria for Adverse Events 
v4.0 and New York Heart Association criteria. Safety data are presented for 
the overall safety population (patients who received at least one dose of study 
treatment) and by treatment period. 
 
3. Results 
3.1 Patients 
The trial profile is shown in Supplementary Fig. 1. Four hundred and eighty-
eight patients were randomised, 483 were included in the safety population, 
and 467 were included in the evaluable ITT population.[3] The de novo group 
comprised 98/483 patients (20.3%) and the non-de novo group 385/483 
patients (79.7%). Four hundred and nine patients completed follow-up 
according to protocol. Baseline characteristics and treatment history are 
shown in Table 1 for the evaluable ITT population and Table 2 for the safety 
population.  
 
3.2 EFS 
After a median follow-up of 36.1 months (range 0–45.9 months), 3-year EFS 
across both randomisation groups in the overall evaluable ITT population was 
90.6% overall (95% confidence interval [CI] 87.4–92.9%) (Fig. 2A), 89.9% in 
Cohort 1 (95% CI 84.9–93.3%) (Fig. 2B), and 91.1% in Cohort 2 (95% CI 
86.6–94.2%) (Fig. 2C). Overall, 46/467 patients (9.9%) had an EFS event by 
the end of follow-up: 16/467 (3.4%) had a local occurrence, 8/467 (1.7%) a 
regional occurrence, 30/467 (6.4%) a distant recurrence and 3/467 (0.6%) had 
contralateral breast cancer (patients could have been counted in more than 
one event-type but only once overall). 
 
3.3 Safety 
Taking into account the H cycles received prior to randomisation, 425/483 
(88.0%) patients in the safety population received all 18 H cycles, with a 
median of 13 on-study. The majority of patients in the de novo group (89/98, 
90.8%) completed all 18 H cycles and, taking into account cycles received 
before randomisation, the majority of non-de novo patients (336/385, 87.3%) 
also completed all 18 H cycles. Forty-three patients in Cohort 1 received H SC 
by SID during the continuation period, with the remainder receiving H IV. In 
Cohort 2, ten patients chose to receive H IV during the continuation period, 
with the remainder receiving H SC via hand-held syringe from an H SC Vial. 
Among the 58/483 patients (12.0%) in the safety population who discontinued 
treatment before the end of the planned 18 cycles, the most common reasons 
for treatment discontinuation were adverse events (22 patients, 4.6%) and 
disease recurrence (14 patients, 2.9%). No deaths occurred on-treatment. A 
total of 409 patients completed follow-up, including 30 of the patients who had 
previously discontinued treatment. 
The most common AEs of any grade were arthralgia (13.7%), asthenia 
(13.7%) and headache (10.4%) (Table 1). No other AEs occurred in ≥10% of 
patients (Table 3). Differences in AE rates between H SC and H IV periods 
during crossover (Table 4) were driven by injection site reactions, and rates 
were similar between H SC and H IV periods when injection site reactions 
were excluded (275/479 [57.4%] and 258/478 [54.0%], respectively). 
Most AEs were grades 1 or 2, with grade 3 events in 45 patients (9.3%) 
(Table 4). No grade 4 or 5 AEs were reported. AEs considered by the 
investigator to be related to H treatment were reported in 213 patients 
(44.1%), and at grade 3 severity in 14 patients (2.9%). Left ventricular 
dysfunction and dyspnoea (two patients each) were the only H-related grade 3 
AEs that occurred in more than one patient. 
SAEs were reported in 19/483 patients (3.9%) (Table 4). Only one (left 
ventricular dysfunction in one Cohort 2 patient during the H SC continuation 
period) was considered by the investigator to be related to H treatment. This 
resulted in temporary discontinuation of study drug; the patient recovered 
completely. All SAEs had resolved by clinical cut-off. 
AEs resulted in treatment discontinuation in 21/483 patients (4.3%), 7/244 
(2.9%) in Cohort 1 and 14/239 (5.9%) in Cohort 2. Left ventricular dysfunction 
(one patient in Cohort 1 and six in Cohort 2), congestive cardiac failure (one 
patient in Cohort 1 and two in Cohort 2) and injection site pain (two patients in 
Cohort 2) were the only AEs that led to discontinuation in more than one 
patient. There were eight deaths during the study, two in Cohort 1 and six in 
Cohort 2. All were attributed to disease recurrence. 
 
3.4 Cardiac AEs 
A total of 49 cardiac AEs were reported in 40/483 patients (8.3%), with left 
ventricular dysfunction (11 patients, 2.3%), palpitations (seven patients, 
1.4%), ejection fraction decreased (seven patients, 1.4%), congestive cardiac 
failure (five patients, 1.0%), bradycardia (three patients, 0.6%) and 
extrasystoles (two patients, 0.4%) being the only cardiac AEs occurring in 
more than one patient (Table 5). Most cardiac events were grades 1 and 2, 
with only one cardiac SAE (left ventricular dysfunction; described above). Only 
four patients had grade 3 cardiac events; three experienced left ventricular 
dysfunction (one in Cohort 1, two in Cohort 2) and one patient in Cohort 2 
experienced congestive heart failure. No patients experienced serious 
congestive heart failure.  
 
4. Discussion 
The PrefHer study demonstrated an overwhelming patient preference (89%) 
for treatment with H SC over H IV during the adjuvant treatment of HER2-
positive early breast cancer, regardless of the method of H SC delivery (SID 
or delivery via a hand-held syringe from an SC Vial,[2,3]) with clear and 
meaningful benefits in time saving for both patients and healthcare 
professionals in addition to patient-reported advantages of convenience and 
less pain/discomfort/side effects.[2–4] SC delivery of a 600 mg fixed dose was 
shown to result in non-inferior trough H serum concentrations and pathological 
complete response compared with body-weight-based IV dosing in the 
HannaH study.[1] EFS was also similar between H SC and H IV after 2 years 
of treatment-free follow-up.[18] Recently, studies including HannaH showed 
that pathological complete response was associated with EFS.[18–20] In the 
current report we describe 3-year efficacy and safety of H SC in the PrefHer 
study. 
Overall, the 3-year EFS rates following H SC and H IV treatment observed in 
both cohorts were consistent with efficacy observed in previous clinical trials 
of adjuvant H therapy for patients with HER2-positive early breast cancer.[21–
24] 
Previous safety analyses of PrefHer, which were limited to the crossover 
period, have indicated that H SC was well tolerated, with no new safety 
signals identified,[2,3] and that safety was not affected by switching from H IV 
to H SC or vice versa.[25] The 3-year results of PrefHer presented here 
confirm these findings. No additional safety signals were identified and safety 
was as expected during the crossover periods and H continuation periods in 
both cohorts. Long-term analyses of cardiac events in phase III trials of H 
show that late congestive heart failure is uncommon, with most events 
occurring during treatment, and that the majority of cardiac events are 
reversible.[26–33] Our data are consistent with these findings, with few grade 
3 cardiac AEs and only one cardiac SAE in 483 patients. There were no 
associations between cardiac safety and method of delivery (SID or hand-held 
syringe from an H SC Vial) or phase of treatment during the trial.  
A limitation of the current study is that, because patients received both H IV 
and H SC and may have switched between the two on one or more 
occasions, analysis of subgroups, e.g. by body weight, would be difficult to 
interpret, and therefore these have not been performed. Previous studies, 
however, have shown that the efficacy and safety of H SC is comparable in 
patients of low and high body weight.[1,18,34] 
H remains a key component of treatment for HER2-positive breast cancer, 
both in the (neo)adjuvant and metastatic settings. Recent long-term data from 
the NeoSphere and APHINITY studies were of particular interest, as they 
suggested a progression-free and (invasive) disease-free survival benefit of 
combining anti-HER2 therapies (pertuzumab and H) with chemotherapy in the 
neoadjuvant and adjuvant settings, respectively.[20,35] The survival benefit of 
H plus pertuzumab and docetaxel is also proven in the metastatic 
setting.[36,37] Combining pertuzumab with H SC may provide further benefits 
and convenience for patients in the future and the safety profile of this 
combination in metastatic breast cancer has been reported in the phase IIb 
SAPPHIRE study [38] and the phase III MetaPHER study.[39] However, as 
observed in PrefHer [2, 3], a small proportion of patients prefer H IV and can 
ask for it. In conclusion, 3-year EFS results following H SC and H IV treatment 
confirm efficacy findings from previous trials of H in the adjuvant setting. H SC 
was well tolerated and no new safety signals were identified compared with 
the known profiles of H IV or H SC from previous reports in HER2-positive 
early breast cancer. 
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Figures and tables 
Table 1 – Patient characteristics (evaluable ITT population).  
a Denominator = 116. b Denominator = 117.c Denominator = 116.  
d Denominator = 110. e Denominator = 459.  
Abbreviations: H, trastuzumab (Herceptin®); ECOG PS, Eastern Cooperative 
Oncology Group performance status; IV, intravenous; SC, subcutaneous. 
 Cohort 1 Cohort 2  
 H SC→ 
H IV 
n = 117 
H IV→ 
H SC 
n = 119 
H SC→  
H IV 
n = 118 
H IV→ 
H SC 
n = 113 
Overall 
N = 467 
Median age, years 
(range) 
54.0 (32–76) 51.0 (28–75) 50.0 (29–78) 53.0 (27–76) 52.0 (27–78) 
Median weight, kg 
(range) 
68.6  
(35.0–12.0)a 
66.0  
(45.0–131.8)b 
67.5 
(49.0–103.8)c 
65.5 
(41.0–117.0)d 
67.0 
(35.0–131.8)e 
Oestrogen receptor 
status, n (%) 
     
Negative 39 (33.3) 40 (33.6) 40 (33.9) 41 (36.3) 160 (34.3) 
Positive 77 (65.8) 79 (66.4) 74 (62.7) 71 (62.8) 301 (64.5) 
Unknown 1 (0.9) 0 4 (3.4) 1 (0.9) 6 (1.3) 
ECOG PS at 
screening, n (%) 
     
0 95 (81.2) 96 (80.7) 99 (83.9) 91 (80.5) 381 (81.6) 
1 22 (18.8) 23 (19.3) 19 (16.1) 21 (18.6) 85 (18.2) 
Not done 0 0 0 1 (0.9) 1 (0.2) 
TNM classification at 
diagnosis, n (%) 
     
T0 1 (0.9) 3 (2.5) 0 1 (0.9) 5 (1.1) 
T1 62 (53.0) 40 (33.6) 47 (39.8) 51 (45.1) 200 (42.8) 
T2 38 (32.5) 57 (47.9) 61 (51.7) 43 (38.1) 199 (42.6) 
T3 8 (6.8) 11 (9.2) 5 (4.2) 12 (10.6) 36 (7.7) 
T4 6 (5.1) 8 (6.7) 3 (2.5) 6 (5.3) 23 (4.9) 
Not assessable/ 
unknown 
2 (1.7) 0 2 (1.7) 0 4 (0.9) 
Lymph node-positive 
at diagnosis, n (%) 
48 (41.0) 66 (55.5) 61 (51.7) 53 (46.9) 228 (48.8) 
H before enrolment,  
n (%) 
     
De novo 27 (23.1) 27 (22.7) 20 (16.9) 20 (17.7) 94 (20.1) 
Non-de novo 90 (76.9) 92 (77.3) 98 (83.1) 93 (82.3) 373 (79.9) 
Previous treatment,  
n (%) 
     
Chemotherapy 117 (100) 119 (100) 117 (99.2) 113 (100) 466 (99.8) 
Radiotherapy 75 (64.1) 74 (62.2) 71 (60.2) 68 (60.2) 288 (61.7) 
Hormonal therapy 50 (42.7) 52 (43.7) 48 (40.7) 44 (38.9) 194 (41.5) 
Lapatinib 0 1 (0.8) 0 1 (0.9) 2 (0.4) 
 
  
Table 2 – Patient characteristics (safety population). 
 a Denominator = 121. b Denominator = 120.c Denominator = 119.  
d Denominator = 115. e Denominator = 475.  
Abbreviations: H, trastuzumab (Herceptin®); ECOG PS, Eastern Cooperative 
Oncology Group performance status; IV, intravenous; SC, subcutaneous. 
 Cohort 1 Cohort 2  
 H SC→ 
H IV 
n = 122 
H IV→ 
H SC 
n = 122 
H SC→  
H IV 
n = 121 
H IV→ 
H SC 
n = 118 
Overall 
N = 483 
Median age, years 
(range) 
55.0 (32–83) 51.0 (28–75) 50.0 (29–78) 53.0 (27–76) 53.0 (27–83) 
Median weight, kg 
(range) 
69.0  
(35.0–120.0)a 
65.7  
(45.0–131.8)b 
67.0  
(49.0–103.8)c 
66.0  
(41.0–117.0)d 
67.0  
(35.0–131.8)e 
Oestrogen receptor 
status, n (%) 
     
Negative 44 (36.1) 40 (32.8) 40 (33.1) 44 (37.3) 168 (34.8) 
Positive 77 (63.1) 82 (67.2) 77 (63.6) 73 (61.9) 309 (64.0) 
Unknown 1 (0.8) 0 4 (3.3) 1 (0.8) 6 (1.2) 
ECOG PS at 
screening, n (%) 
     
0 97 (79.5) 98 (80.3) 102 (84.3) 93 (78.8) 390 (80.7) 
1 25 (20.5) 24 (19.7) 19 (15.7) 14 (20.3) 92 (19.0) 
Not done 0 0 0 1 (0.8) 1 (0.2) 
TNM classification at 
diagnosis, n (%) 
     
T0 1 (0.8) 3 (2.5) 0 1 (0.8) 5 (1.0) 
T1 64 (52.5) 41 (33.6) 48 (39.7) 51 (43.2) 204 (42.2) 
T2 40 (32.8) 59 (48.4) 63 (52.1) 46 (39.0) 208 (43.1) 
T3 8 (6.6) 11 (9.0) 5 (4.1) 13 (11.0) 37 (7.7) 
T4 7 (5.7) 8 (6.6) 3 (2.5) 7 (5.9) 25 (5.2) 
Not assessable/ 
unknown 
2 (1.6) 0 2 (1.7) 0 4 (0.8) 
Lymph node-positive 
at diagnosis, n (%) 
51 (41.8) 67 (54.9) 63 (52.1) 57 (48.3) 238 (49.3) 
H before enrolment,  
n (%) 
     
De novo 28 (23.0) 29 (23.8) 21 (17.4) 20 (16.9) 98 (20.3) 
Non-de novo 94 (77.0) 93 (76.2) 100 (82.6) 98 (83.1) 385 (79.7) 
Previous treatment,  
n (%) 
     
Chemotherapy 122 (100) 122 (100) 120 (99.2) 118 (100) 482 (99.8) 
Radiotherapy 76 (62.3) 76 (62.3) 73 (60.3) 70 (59.3) 295 (61.1) 
Hormonal therapy 50 (41.0) 55 (45.1) 50 (41.3) 45 (38.1) 200 (41.4) 
Lapatinib 0 1 (0.8) 1 (0.8) 1 (0.8) 3 (0.6) 
  
Table 3 – Adverse events in ≥5% patients in any period (safety 
population). a Could be counted once per grade but ≥ once overall. 
Abbreviations: AE, adverse event; H, trastuzumab (Herceptin®); IV, 
intravenous; SC, subcutaneous; SID, single-use injection device. 
 Crossover  Continuation Overall 
Patients, n (%)a 
H SC 
period 
n = 479 
H IV 
period 
n = 478 
P value  
(H SC 
period  
vs. H IV 
period) 
H IV or  
H SC 
(syringe) 
n = 440 
H SC (SID) 
n = 43 N = 483 
Any AE 300 (62.6) 258 (54.0) 0.01 223 (50.7) 12 (27.9) 388 (80.3) 
Arthralgia 25 (5.2) 27 (5.6) 0.78 22 (5.0) 1 (2.3) 66 (13.7) 
Asthenia 30 (6.3) 25 (5.2) 0.58 20 (4.5) 0 66 (13.7) 
Headache 20 (4.2) 17 (3.6) 0.74 21 (4.8) 0 50 (10.4) 
Hot flush 22 (4.6) 17 (3.6) 0.51 8 (1.8) 1 (2.3) 45 (9.3) 
Fatigue 19 (4.0) 18 (3.8) 1.00 13 (3.0) 0  44 (9.1) 
Nausea 25 (5.2) 14 (2.9) 0.10 9 (2.0) 1 (2.3) 39 (8.1) 
Injection site pain 32 (6.7) 0 <0.01 6 (1.4) 2 (4.7) 37 (7.7) 
Diarrhoea 16 (3.3) 12 (2.5) 0.57 12 (2.7) 0 35 (7.2) 
Pain in extremity 19 (4.0) 7 (1.5) 0.03 8 (1.8) 0 31 (6.4) 
Injection site erythema 28 (5.8) 0 <0.01 4 (0.9) 0 30 (6.2) 
Injection site reaction 29 (6.1) 0 <0.01 2 (0.5) 0 29 (6.0) 
Nasopharyngitis 11 (2.3) 10 (2.1) 1.00 12 (2.7) 1 (2.3) 29 (6.0) 
Erythema 17 (3.5) 6 (1.3) 0.03 7 (1.6) 1 (2.3) 26 (5.4) 
 
 
 
  
Table 4 – Adverse event profile (safety population). a Could be counted 
once per grade but ≥ once overall. 
Abbreviations: AE, adverse event; H, trastuzumab (Herceptin®); IV, 
intravenous; SC, subcutaneous; SAE, serious adverse event; SID, single-use 
injection device. 
 
Crossover  
P value  
(H SC 
period  
vs. H IV 
period) 
Continuation Overall 
Patients with 
≥ 1 AE, n (%)a 
H SC 
period 
n = 479 
H IV period 
n = 478 
H IV or  
H SC 
(syringe) 
n = 440 
H SC (SID) 
n = 43 N = 483 
Median H 
cycles, n 
4.0 4.0 – 5.0 2.0 13.0 
Any AE 300 (62.6) 258 (54.0) 0.01 223 (50.7) 12 (27.9) 388 (80.3) 
Grade 1 262 (54.7) 206 (43.1) <0.01 175 (39.8) 10 (23.3) 360 (74.5) 
Grade 2 119 (24.8) 110 (23.0) 0.54 85 (19.3) 5 (11.6) 214 (44.3) 
Grade 3 17 (3.5) 16 (3.3) 1.00 16 (3.6) 1 (2.3) 45 (9.3) 
Grade 4 0 0 – 0 0 0 
Grade 5 0 0 – 0 0 0 
AE with 
suspected 
causal 
relationship to 
study 
medication 
163 (34.0) 53 (11.1) <0.01 60 (13.6) 4 (9.3) 207 (42.9) 
Discontinuation 
for AE 
5 (1.0) 6 (1.3) 0.77 10 (2.3) 0 21 (4.3) 
Any SAE 4 (0.8) 4 (0.8) 1.00 11 (2.5) 1 (2.3) 19 (3.9) 
Treatment-
related SAE 
0 0 – 1 (0.2) 0 1 (0.2) 
  
Table 5 – Cardiac adverse events (safety population). a Could be counted 
once per grade but ≥ once overall. b Cardiac disorders not listed: bradycardia 
(three patients), extrasystoles (two patients), angina pectoris, cardiomyopathy, 
diastolic dysfunction, heart valve incompetence, left ventricular hypertrophy, 
mitral valve incompetence, sinus bradycardia, tachycardia (one patient each). 
c Ejection fraction decreased (seven patients), ejection fraction abnormal, 
electrocardiogram change (one patient each). 
Abbreviations: AE, adverse event; H, trastuzumab (Herceptin®); IV, 
intravenous; SC, subcutaneous; SID, single-use injection device. 
 
Crossover Continuation Overall 
Patients with 
≥ 1 AE, n (%)a 
H SC 
period 
n = 479 
H IV period 
n = 478 
H IV or  
H SC 
(syringe) 
n = 440 
H SC (SID) 
n = 43 n = 483 
Any cardiac AE 12 (2.5) 15 (3.1) 17 (3.9) 0 40 (8.3) 
Grade 1 9 (1.9) 11 (2.3) 11 (2.5) 0 28 (5.8) 
Grade 2 2 (0.4) 3 (0.6) 6 (1.4) 0 10 (2.1) 
Grade 3 1 (0.2) 2 (0.4) 1 (0.2) 0 4 (0.8) 
Cardiac 
disorders (any 
grade)b 
8 (1.7) 14 (2.9) 14 (3.2) 0 33 (6.8) 
Left ventricular 
dysfunction 
2 (0.4) 5 (1.0) 4 (0.9) 0 11 (2.3) 
Palpitations 3 (0.6) 2 (0.4) 2 (0.5) 0 7 (1.4) 
Congestive 
heart failure 
2 (0.4) 0 3 (0.7) 0 5 (1.0) 
Investigations 
(any grade)c 
4 (0.8) 3 (0.6) 3 (0.7) 0 9 (1.9) 
 
 
  
Fig. 1 – Study design.[2]  Reprinted from The Lancet Oncology, 14, Pivot X, 
Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, 
Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield 
L, for the PrefHer Study Group, Preference for subcutaneous or intravenous 
administration of trastuzumab in patients with HER2-positive early breast 
cancer (PrefHer): an open-label randomised study, 962–970, Copyright 
(2013), with permission from Elsevier. 
 
Fig. 2 – Three-year event-free survival in (A) the overall evaluable ITT 
population, (B) the evaluable ITT population of Cohort 1, and (C) the 
evaluable ITT population of Cohort 2.  
Abbreviations: CI, confidence interval; EFS, event-free survival; H, 
trastuzumab (Herceptin®); IV, intravenous; SC, subcutaneous; SID, single-use 
injection device. 
 
Appendix D: Supplementary Fig. 2 – Trial profile. a Two patients in Cohort 
1 in the H SC SID/H IV group were randomised but not treated due to non-
compliance with eligibility criteria (and investigator’s decision). b Two patients 
in Cohort 1 in the H IV/H SC SID group were randomised but not treated due 
to an AE and disease recurrence. c One patient in Cohort 2 in the H IV/H SC 
Vial group was randomised but not treated due to non-compliance with 
eligibility criteria.  
d Three patients in Cohort 1 in the H SC SID/H IV group, who were reported to 
have completed treatment at the primary analysis, had in fact discontinued 
treatment based on investigator’s decision.    
Abbreviations: H, trastuzumab (Herceptin®); IV, intravenous; SC, 
subcutaneous. 
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Appendix B: PrefHer study investigators (Pivot X, Gligorov J, Müller V, et 
al. Patients' preferences for subcutaneous trastuzumab versus 
conventional intravenous infusion for the adjuvant treatment of HER2-
positive early breast cancer: final analysis of 488 patients in the 
international, randomized, two-cohort PrefHer study. Ann Oncol 
2014;25(10):1979–87).  
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Appendix C: Patient eligibility criteria (Pivot X, Gligorov J, Müller, V et al. 
Preference for subcutaneous or intravenous administration of 
trastuzumab in patients with HER2-positive early breast cancer 
(PrefHer): an open-label randomised study. Lancet Oncol 
2013;14(10):962–70 and Pivot X, Gligorov J, Müller V, et al. Patients' 
preferences for subcutaneous trastuzumab versus conventional 
intravenous infusion for the adjuvant treatment of HER2-positive early 
breast cancer: final analysis of 488 patients in the international, 
randomized, two-cohort PrefHer study. Ann Oncol 2014;25(10):1979–87). 
Eligible patients were women aged ≥18 years with HER2-positive 
(immunohistochemistry 3+ or in situ hybridisation-positive), histologically 
confirmed primary invasive breast adenocarcinoma, no evidence of residual, 
locally recurrent, or metastatic disease after completion of surgery and 
chemotherapy (neoadjuvant or adjuvant), an Eastern Cooperative Oncology 
Group performance status of 0 or 1, and a baseline left ventricular ejection 
fraction of ≥55% before the first trastuzumab dose. HER2-positivity was 
assessed by local laboratories with validated assays, according to 
recommendations outlined in the summary of product characteristics for IV 
trastuzumab. Radiotherapy or hormone therapy was allowed. Patients had to 
have been either trastuzumab-naïve (de novo group) or already receiving 
intravenous trastuzumab (non-de novo group) as part of their (neo)adjuvant 
therapy, and they had to have at least eight out of the total 18 planned 3-
weekly trastuzumab cycles remaining before enrolment. 
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Highlights: 
 3-year event-free survival data in PrefHer were consistent with previous 
trials.  
 The overall safety profile during adjuvant treatment was as expected. 
 H SC was well tolerated and no new safety signals were identified. 
 
 
 
 
 
 
